FBT logo

FBTFirst Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund

$222.75
$3.04
(1.34%)
Today
Closed $222.75
$0.00
(0.00%)
After Hours
Updated: 05:55 PM EDT
Vol15,243.00
52W High$228.14
52W Low$157.52
50

Neutral Sentiment

How do you feel about FBT?

News
all
press releases
ONC Stock Gains As BeOne Medicines Wins US Nod For BEQALZI In Rare Lymphoma
The FDA approved BEQALZI in the treatment of certain mantle cell lymphoma patients on Wednesday.
Stocktwits
News Placeholder
More News
News Placeholder
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Smart Beta ETF report for FBT
Zacks
News Placeholder
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Sector ETF report for FBT
Zacks
News Placeholder
SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced
Leerink analyst Joseph Schwartz said the initial data released by the company in genetic diseases DM1 and FSHD1 are "a bit of a mixed bag."
Stocktwits
News Placeholder
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study
Data from the study cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks associated with the gene therapy.
Stocktwits
News Placeholder
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Smart Beta ETF report for FBT
Zacks
News Placeholder
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Sector ETF report for FBT
Zacks
News Placeholder
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition
The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.
Stocktwits
News Placeholder
Why Did SRPT Stock Rise 6% In Pre-Market Today?
The company announced positive three-year topline results from its EMBARK study evaluating ELEVIDYS, a gene therapy for ambulatory patients with DMD.
Stocktwits
News Placeholder
IBRX Stock Gains Pre-Market After A Volatile Trading Session Following Phase 2 Glioblastoma Trial Update: Retail Backs ImmunityBio’s Cancer Research
Patrick Soon Shiong, ImmunityBio’s founder, took to X on Saturday to clarify what the update signified.
Stocktwits
<
1
2
...
>

Advertisement|Remove ads.